Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's pretty stunning.
ILT
I say great buying opportunity! Too late for me but for others...
ILT
Correction appears to be a fake profile. Jeez....
Now I've seen everything. Oscar De La Hoya making a bear case for Amarin. Claims patent expiration 2029 substantial liability going forward, and it would take years to ramp up. Among other unforgiving digs at Management. Go figure!
ILT
Just adds to Amarin's value by default IMO.
ILT
Stockboy,
Thank you! for sharing. These numbers are terrific, especially with all the moving parts that need to come together for these numbers to show up:
1. The timing of patient visits with their doctors.
2. Doctors being aware of Reduct-it.
3. Back and forth communications between Doctor's office and Insurance provider/ Prior-Auth etc.
4. Actual script date filled.
Once that first script is filled, we have patients for life. Boy is WS oblivious.
ILT
How typical, PPS trades lower on news of securing nondilutive funds.
ILT
TTE,
I'm afraid the bears will twist it for their own ends.
ILT
My brother was just at a small pharma dinner with two Cardiologists in attendance. One who's also connected to academia. These doctors see a high volume of patients which is why the drug companies taget them for speaking dinners. Guess what my brother asked them? 'Are you writing Vascepa?" Answer: "All day long!".
ILT
sts66,
I'd be curious to know if any of these Doctors saw the supplemental data before offering their commentary?
ILT
Excellent!
ILT
Bravo!
ILT
Gotcha. Really like your take charge approach for your own health.
ILT
sts66,
Are you referencing the precursor form that I take nicotinomide riboside brand name True Naigen? If not, the issue may be specific to the compound you tried?
ILT
December doesn't appear likely for any of these to happen. I was hoping we would see $19.70 before eOY.
ILT
$AMRN 's new SVP & Chief Corporate Compliance Officer wrote the book on off-label marketing...literally.
— TerraPharma (@TerraPharma1) December 10, 2018
Off-Label Communication: A Guide to Sales and Marketing Compliance, 4th Edition, Food & Drug Law Institute. By D. Dunham. Published 2014
BB, here something you would appreciate:
$AMRN 's new SVP & Chief Corporate Compliance Officer wrote the book on off-label marketing...literally.
— TerraPharma (@TerraPharma1) December 10, 2018
Off-Label Communication: A Guide to Sales and Marketing Compliance, 4th Edition, Food & Drug Law Institute. By D. Dunham. Published 2014
Never new NNT for Statins was 104. Point well taken. Wow.
ILT
sts66,
Are you familiar with NR (B3)?
ILT
The medical professional is in a sad place, if we're making excuses as to why Doctors aren't yet onboard.
ILT
Wow, that's disturbing. Well, so much for early adaption. I have no faith in the medical community at large.
ILT
Not making a big deal of it..Many of us in our circle family, doctors, patients of theirs are taking their Vascepa in one shot at night.
ILT
Yup, certainly good genes have to be in the picture. I've shared in previous posts my regimen for sustainable health and longevity.
ILT
isaeed,
I was thinking about that. More than one BP could come together to raise the funds needed to make a deal.
ILT
HerbieRay,
If the healthcare cost article I just posted doesn't elucidate, just how definitive your prediction will come to pass, I don't know what else can.
ILT
Highly informative article that illustrates just how urgently Vascepa needs the expanded label indication and a huge market uptake. I borrowed someone else's post from another board cut and pasted below:
Quote:
MUST READ - Comprehensive article on rising healthcare costs.. compare to the chart below:
__________________________________________________________________
The article is full of supporting links. It clearly shows how our current path is unsustainable. Treating cancer is important to fiscal sustainability of government healthcare systems.
Excerpt:
Quote:
Between 1983 and 1992, health care costs rose by an average of 9.9 percent each year. Home health care prices increased by 18.3 percent per year. In 1986, Congress passed the Emergency Medical Treatment and Labor Act. It forced hospitals to accept anyone who showed up at the emergency room. If the patient couldn't pay, Medicaid covered it. Prescription drug costs rose by 12.1 percent a year. One reason is that Congress allowed prescription drug companies to advertise on television.
Between 1993 and 2010, prices rose by an average of 6.4 percent a year. In the early 1990s, health insurance companies tried to control costs by spreading the use of HMOs once again. Congress then tried to control costs with the Balanced Budget Act in 1997. Instead, it forced many health care providers out of business. Because of this, Congress relented on payment restrictions in the Balanced Budget Refinement Act in 1999 and the Benefits Improvement and Protection Act of 2000. The Act also extended coverage to children through the Children's Health Insurance Program.
After 1998, people rebelled and demanded more choice in providers. As demand increased again, so did prices. Between 1997 and 2007, drug prices tripled, according to a study in Health Affairs.
One reason is that pharmaceutical companies invented new types of prescription drugs. They advertised straight to consumers and created additional demand. The number of drugs with sales that topped $1 billion increased to 52 in 2006 from six in 1997. The U.S. government approved expensive drugs even if they were not much better than existing remedies. Other developed countries were more cost-conscious, according to The New York Times.
In 2003, the Medicare Modernization Act added Medicare Part D to cover prescription drug coverage. It also changed the name of Medicare Part C to the Medicare Advantage program. The number of people using those plans tripled to 17.6 million by 2016. Those costs rose faster than the cost of Medicare itself.
The nation’s reliance on the health insurance model increased administration costs. A 2003 study found that administration made up 30 percent of U.S. health care costs. It's twice the administrative costs in Canada. About half of that is due to the complexity of billing.
For example, U.S. private doctors' offices need seven people to do billing for every 10 physicians. A big reason is that there are so many types of payers. In addition to Medicare and Medicaid, there are thousands of different private insurers. Each has its own requirements, forms, and procedures. Hospitals and doctors must also chase down people who don't pay their portion of the bill. That doesn't happen in countries with universal health care.
The reliance on corporate private insurance created health care inequality. Those without insurance often couldn't afford visits to a primary care physician. By 2009, half of the people (46.3 percent) who used a hospital said they went because they had no other place to go for health care. The Emergency Medical Treatment and Active Labor Act required hospitals to treat anyone who showed up in the emergency room. These uninsured patients cost hospitals a staggering $10 billion a year. The hospitals passed this cost along to Medicaid.
Preventable Chronic Diseases
The second cause of rising health care costs is an epidemic of preventable diseases. The four leading causes of death are heart disease, cancer, chronic obstructive pulmonary disorder, and stroke. Chronic diseases cause all of them. They can either be prevented or would cost less to treat if caught in time. Risk factors for heart disease and strokes are poor nutrition and obesity. Smoking is a risk factor for lung cancer (the most common type) and COPD. Obesity is also a risk factor for the other common forms of cancer.
These diseases cost an extra $7,900 per person. That’s five times more than the health care costs for a healthy person. The average cost of treating diabetes, for example, is $26,971 per family. These diseases are difficult to manage because patients get tired of taking the various medications. Those who cut back find themselves in the emergency room with heart attacks, strokes, and other complications. (Source: “The Impact of Chronic Diseases on Health Care,” For a Healthier America, 2014.)
Recent research found that even Alzheimer's disease might be preventable. The study, called SPRINT MIND, found that high blood pressure could worsen dementia caused by Alzheimer's.
https://www.thebalance.com/causes-of-rising-healthcare-costs-4064878
ILT
RR,
I didn't even know Statins come in doses that high. I wonder how closely side effects correlate to dosage strength? In any event, I'm glad you're doing well! As for bulking up using CO-Q10, now that's interesting to me. I'm going to dig into it further. Thanks for sharing.
ILT
BB, well said.
ORBAPU,
I've always been a piller of good health. I'm a huge believer of using modern medicine to enhance my profile as part of my ant-aging and prevention objectives. I've never had food sensitivities allergies of any kind, nor have I ever had any side effects on 10 mgs of Crestor. Perhaps CO-Q10 would have shown up on my radar if it had.
Thanks for sharing the links.
ILT
CBB, appreciate the follow-up. I'll take a look.
ILT
CBB,
I've been on Statin crestor for many years. If Co-Q10 was important to add, I would have been advised to do so. It's a waist of money unless someone can supply recognized studies that support otherwise.
ILT
Thanks for sharing!
CBB, great points!
From the comments I'm reading, I feel you're all still missing the point. PFE paid Warner-Lambert $98.00 PPS. It was a one drug pony, but it wasn't just any drug, it was the greatest selling drug in history. Reduct-it results have been described as "stunning. Dr.Bhaat said, echoed by many others at this point, that Vascepa will fundamentally change how cardiovascular disease is treated. Does anyone believe for a second, that BP isn't convinced that Vascepa will receive FDA approval? That they wouldn't know how quickly they could move it through the process to label expansion? That they haven't crunched the numbers to know how much they would stand to make on such a drug? How many Zumantu articles do you have to read to understand, that Vascepa will be the gift that "keeps giving? Are some suggesting, that offers would come in at a significant discount because Amarin still has some things to prove? Amarin's valuation is not what JT or what shareholders think it should be. It's what the market will pay, and the market is quite efficient at figuring it out. Someone suggested, that a BP wouldn't want to show their hand now for fear of getting into a bidding war. Ok, is there any better time? Someone will always have to go first. I would hate to be a BP that blew an opportunity to have control of a cash-cow that guarantees blockbuster revenue for the next 11 years. Time is ticking for everyone. Amarin, BP's, Shareholders, and most of all, the patients.
P.S. The PPS today shows longs are smarter than WS. But don't count on BP's keeping their heads in the sand for much longer. Don't be surprised, if you wake up one morning to find the stock surged to triple digits. They don't happen with advanced warnings. Those who are out or just waiting on the sidelines should fear to miss the train. It can happen at any time.
ILT
Whether Amarin is BO or GIA, we can all agree, we want the prevailing scenario to give us the highest PPS. With that in mind, the MB has made strong arguments to GIA. What hasn't been emphasized, is that BP's are under "enormous pressure" from their current ledgers, to act with a far greater sense of urgency, IMO, than to dilly dally around for Amarin to make further progress. For what purpose?!! The inflexion point was on Nov. 10th. We can say the recent cash raise was the second.
As far as BP's are concerned, Amarin's Vascepa is 100% derisked. All the risk has shifted to the patent expiration. Let's not kid ourselves, we all know the enormous scale that BP's have to monetize products.
My brother and I caught up and watched the Golden State Warriors last night. A diabetes drug commercial came on, and he made it a point to say how great the commercial was. The way it makes use of an old Michael Jackson sampling in the background, which sticks to you afterwards. Another one from Ozempic, which one feels compelled to see along, way after the commercial is over. In comparison, he thought Vascepa's commercial "sucked".
BP's have taken on huge financial liabilities in recent years, buying up emerging cancer therapies, only to find recently, that some are causing more harm than good. So why wouldn't say a PFE, offer 100 PPS today? or higher? I would argue, that Amarin could entertain "much higher triple digit" offers today with a much longer Patent window" than say a year from now. "The Clock is ticking", and everyone knows it.
JMO
ILT
$AMRN just saw my PCP 4 my annual physical. Talked about Vascepa. He loved it. He's buying stock today. He said just the diabetics alone are HUGE.
— PantherFan (@PickingMyOwn) December 6, 2018
AH $17.18 not bad!
Zumantu,
Frankly, I had the same inclination. That's why I had reasoned earlier, that supports can provide greater impact through social media "without" stepping on Amarin's toes. Amarin has enough on its plate than to be distracted by rogue forces to reign in. I'll mention it again, check out JohnCapello TerraPharma, Anonymous, and numerous others on Twitter. You'd be surprised at the "high volume of content", many of which I'm seeing for the first time posted on a daily basis. Before making any judgement, I recommend people to jump over there, and see how these supporters are making the most of content marketing without any risk of improprieties. JMO
ILT